Oncternal Therapeutics (NASDAQ:ONCT) Price Target Cut to $18.00 by Analysts at HC Wainwright

Oncternal Therapeutics (NASDAQ:ONCT) had its price objective cut by HC Wainwright from $19.00 to $18.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, StockNews.com began coverage on Oncternal Therapeutics in a research report on Wednesday, August 7th. They set a hold rating on the stock.

Oncternal Therapeutics Price Performance

Shares of NASDAQ:ONCT opened at $3.80 on Monday. Oncternal Therapeutics has a 1 year low of $3.80 and a 1 year high of $13.14. The company has a market cap of $11.25 million, a P/E ratio of -0.31 and a beta of 1.36. The stock’s fifty day moving average price is $6.98 and its 200-day moving average price is $8.25.

Oncternal Therapeutics (NASDAQ:ONCT) last released its quarterly earnings data on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, beating the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 107.67% and a negative net margin of 3,160.73%. The company had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.24 million. During the same period last year, the firm posted ($3.00) earnings per share. On average, sell-side analysts anticipate that Oncternal Therapeutics will post -11.63 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics as of its most recent SEC filing. 16.05% of the stock is owned by institutional investors and hedge funds.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.